SCHEMBL913147

SCHEMBL913147

c1ccc2cc3nc4ccccc4cc3cc2c1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.79
HPGD P15428 3/20 0.79
MAPT P10636 3/20 0.79
GLA P06280 2/20 0.79
ACHE P22303 2/20 0.79
NQO2 P16083 3/20 0.67
HTR3A P46098 1/20 0.61
KMT2A Q03164 4/20 0.48
KDM4E B2RXH2 2/20 0.48
GAA P10253 2/20 0.48
NPC1 O15118 2/20 0.48
LMNA P02545 2/20 0.48
POLB P06746 2/20 0.48
PTBP1 P26599 1/20 0.48
RAB9A P51151 1/20 0.48
RCE1 Q9Y256 1/20 0.48
PDE10A Q9Y233 1/20 0.47
ESR1 P03372 2/20 0.45
ESR2 Q92731 2/20 0.45
TDP1 Q9NUW8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19199007 0.97 ALDH1A1 (0.75) ALDH1A1HPGDMAPTGLAACHE
SCHEMBL13156486 0.97 MAPT (0.83) ALDH1A1HPGDMAPTGLAACHE
SCHEMBL29379154 0.97 MAPT (0.83) ALDH1A1HPGDMAPTGLAACHE
SCHEMBL13156489 0.92 MAPT (0.83) ALDH1A1HPGDMAPTGLAACHE
Anthracene SCHEMBL9879830 0.92 MAPT (0.94) ALDH1A1HPGDMAPTGLAACHE
SCHEMBL11688588 0.92 NQO2 (0.68) ALDH1A1HPGDMAPTGLAACHE
Acridine SCHEMBL1772714 0.89 ALDH1A1 (1.00) ALDH1A1HPGDMAPTGLAACHE
Acridine SCHEMBL8339 0.89 ALDH1A1 (1.00) ALDH1A1HPGDMAPTGLAACHE
Acridine SCHEMBL29352289 0.89 ALDH1A1 (1.00) ALDH1A1HPGDMAPTGLAACHE
Acridine SCHEMBL3045498 0.89 ALDH1A1 (1.00) ALDH1A1HPGDMAPTGLAACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1792605-A1 Use of at least a cationic cyanine derivative for use in hair dyeing, composition containg it process of treating keratinic fibres using the same composition, kit and use thereof L'Oréal (FR) 2007-06-06 EP claimed
JP-3172522-B2 2001-06-04 JP claimed
US-5338847-A Hydrolytically stable chemiluminescent labels and their conjugates, and assays therefrom by adduct formation LONDON DIAGNOSTICS, INC. (US) 1994-08-16 US claimed
US-5321136-A Peri substituted fused ring chemiluminescent labels and their conjugates, and assays therefrom LONDON DIAGNOSTICS, INC. (US) 1994-06-14 US claimed
US-5290936-A Indicators or labels for antibodies or medical diagnosis LONDON DIAGNOSTICS, INC. (US) 1994-03-01 US claimed
US-5284951-A Aryl ester, thioester or amide of carboxylic acid substituted heterocyclic ring; quaternary compounds LONDON DIAGNOSTICS, INC. (US) 1994-02-08 US claimed
US-5281712-A Ammonium substituted chemiluminescent labels and their conjugates, and assays therefrom LONDON DIAGNOSTICS, INC. (US) 1994-01-25 US claimed
EP-0332190-A2 Condensed quinoline system compound, condensed acridine system compound, process for preparing the same, and carcinostatic composition containing the same MECT CORPORATION (JP) 1989-09-13 EP claimed
WO-1989006231-A1 ASSAYS UTILIZING IMPROVED CHEMILUMINESCENT ESTERS, THIOESTERS AND AMIDES LONDON DIAGNOSTICS, INC. (US) 1989-07-13 WO claimed
EP-0322926-A2 Assays utilizing improved chemiluminescent esters, thioesters and amides LONDON DIAGNOSTICS, INC. (US) 1989-07-05 EP claimed
JP-1228965-A None JP disclosed
WO-2025096599-A1 MEASUREMENT OF MULTIPLE ANALYTES USING ACRIDINIUM LABELS SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) 2025-05-08 WO disclosed
US-11066351-B2 Organic compound, three-dimensional organic framework formed by using organic compound, separation sieve and optical layer, which comprise organic framework, and optical device comprising optical layer as optical amplification layer IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY) (KR) 2021-07-20 US disclosed
US-10862046-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2020-12-08 US disclosed
US-20190031586-A1 ORGANIC COMPOUND, THREE-DIMENSIONAL ORGANIC FRAMEWORK FORMED BY USING ORGANIC COMPOUND, SEPARATION SIEVE AND OPTICAL LAYER, WHICH COMPRISE ORGANIC FRAMEWORK, AND OPTICAL DEVICE COMPRISING OPTICAL LAYER AS OPTICAL AMPLIFICATION LAYER INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY (KR) 2019-01-31 US disclosed
EP-0332190-A3 CONDENSED QUINOLINE SYSTEM COMPOUND, CONDENSED ACRIDINE SYSTEM COMPOUND, PROCESS FOR PREPARING THE SAME, AND CARCINOSTATIC COMPOSITION CONTAINING THE SAME MECT CORPORATION (JP) 1991-04-24 EP disclosed
EP-0332190-A2 Condensed quinoline system compound, condensed acridine system compound, process for preparing the same, and carcinostatic composition containing the same MECT CORPORATION (JP) 1989-09-13 EP disclosed
EP-0332190-A2 Condensed quinoline system compound, condensed acridine system compound, process for preparing the same, and carcinostatic composition containing the same MECT CORPORATION (JP) 1989-09-13 EP disclosed
JP-H01228965-A CONDENSED QUINOLINE AND CONDENSED ACRIDINE, THEIR PRODUCTION AND ANTICANCER AGENT CONTAINING SAID COMPOUNDS MECT CORP 1989-09-12 JP disclosed
EP-0322926-A2 Assays utilizing improved chemiluminescent esters, thioesters and amides LONDON DIAGNOSTICS, INC. (US) 1989-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11066351-B2 Organic compound, three-dimensional organic framework formed by using organic compound, separation sieve and optical layer, which comprise organic framework, and optical device comprising optical layer as optical amplification layer OR10J3, POF1B, ORC3 ALDH1A1 2899/4885HPGD 4615/4885MAPT 3445/4885
US-20190031586-A1 ORGANIC COMPOUND, THREE-DIMENSIONAL ORGANIC FRAMEWORK FORMED BY USING ORGANIC COMPOUND, SEPARATION SIEVE AND OPTICAL LAYER, WHICH COMPRISE ORGANIC FRAMEWORK, AND OPTICAL DEVICE COMPRISING OPTICAL LAYER AS OPTICAL AMPLIFICATION LAYER OR10J3, POF1B, ORC3 ALDH1A1 2899/4885HPGD 4615/4885MAPT 3445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.